RESEARCH SECTOR
Pharma IT
Technology plays an increasingly significant role in the pharmaceutical industry, from drug discovery to patient engagement. We are interested in IT solutions that accelerate pharmaceutical research, improve clinical trials and enhance drug delivery and patient care.
Discover the latest trends and technologies shaping Pharma IT
"*" indicates required fields
Key themes and focus areas
The pharmaceutical industry is experiencing a digital transformation. The emergence of specialty therapeutics, increased regulatory constraints and the focus on subgroups in various therapeutic areas has led to an explosion of information. In all these domains, digital technologies provide the ability to rapidly and easily collect, store, analyze and transmit data on a large scale, unlocking huge potential in drug discovery, clinical development, commercialization, value-based care and patient safety. EDIT TEST
- Drug discovery
- Contract manufacturing organization (CMO)
- Contract development and manufacturing organization (CDMO)
- Artificial intelligence and analytics
- Clinical trial technology
- Quality management
- Regulatory affairs
- Supply chain logistics
- Medical affairs
- Market access and hub services
- Health economics outcomes research (HEOR)
- Real-world data (RWD)
- Real-world evidence (RWE)
Pharma IT uses technology and information systems to support various functions in the pharmaceutical industry, including research and development, manufacturing, regulatory compliance, supply chain management, and marketing and commercialization. Pharma IT also plays a crucial role in ensuring compliance with industry regulations, such as those imposed by the FDA and the European Medicines Agency, with accurate records and audit processes.
Our pharma IT focus encompasses tech companies that enable pharmaceutical companies to improve productivity, ensure regulatory adherence, and drive innovation from drug discovery through commercialization.
Our sector leaders
Joseph Munda
Managing Director
Matthew Nicklin
Managing Director, Office of the President
Tracy Marshbanks
Managing Director
Andrew Walsh
Managing Director
Walid Elmekki
AssociateFeatured insights and research reports
What the second Trump term could mean for pharma IT
Joseph Munda, Walid Elmekki
Validation tech provides critical protection and a compelling opportunity
Joseph Munda, Walid Elmekki
Clinical trial supply challenges create opportunity for tech
Joseph Munda, Walid Elmekki
Line of “site” to better drug development: Site-centric clinical trial tech
Joseph Munda
Technology is key in medical affairs’ rise as pharma’s third pillar
Joseph Munda
Mind’s role in therapeutics, wellness means opportunity for cognitive assessment technology
Joseph Munda
Venture capital activities
Applied StemCell is a leading CRO/CDMO specializing in cell and gene therapy. Leveraging its proprietary TARGATT genome editing and iPSC platform, the company is dedicated to supporting clients in research, preclinical development, and clinical manufacturing for novel therapeutics. ASC is committed to offering a platform enabling significant cost reductions in cell drug development, delivering ready-to-use cell medicine, and, most importantly, saving human lives.
Sware
www.sware.comDigital validation and process automation across the healthcare, life sciences and medical device industries
Learn more Sware
www.sware.comDigital validation and process automation across the healthcare, life sciences and medical device industries
Sware’s mission is to rescue life sciences companies from the grip of validation debt; the unpaid cost of release, testing, GxP, and business requirements. The Res_Q software platform offers a complete validation solution. Res_Q eliminates validation debt and ensures peace of mind in an increasingly complex technology ecosystem.
Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management.
VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia.
Relevant advisory transactions
Exclusive financial advisor
COPILOT has received investment from QHP Capital
First Analysis acted as the exclusive financial advisor to COPILOT Provider Support Services, LLC, in QHP Capital’s investment in the company.First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like COPILOT. The First Analysis team worked closely with the co-founders and management team to optimally position the company and find the best partner to help COPILOT to continue to achieve its objectives.
About COPILOT:
COPILOT is a digital-first patient-centric reimbursement hub services platform intended to support the relationship between patients, health care providers and pharmaceutical and device manufacturers.
About QHP Capital:
QHP Capital is an investor in technology and services companies in the life sciences and healthcare sectors. QHP Capital spun out of NovaQuest Capital Management, which was formed in 2000 with the vision of building an investment platform to provide strategic capital and industry expertise in partnership with strong management teams.
Exclusive financial advisor
Trialscope
Trialscope has been sold to Informa Pharma Intelligence
Learn moreExclusive financial advisor
Trialscope has been sold to Informa Pharma Intelligence
First Analysis worked with many strategic and financial parties during the COVID-19 pandemic to drive a rapid outcome that met TrialScope’s financial and strategic goals.
About Trialscope:
TrialScope gives your clinical trial data superpowers. The TrialScope Transparency Cloud makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment.
About Informa Pharma Intelligence:
Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet In Vivo and most recently TrialScope – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth. With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers.
Exclusive financial advisor
PrescribeWellness
Has been sold to Tabula Rasa Healthcare
$150,000,000
Learn moreExclusive financial advisor
PrescribeWellness has been sold to Tabula Rasa Healthcare
$150,000,000
First Analysis acted as the exclusive financial advisor in the sale of PrescribeWellness, a leading cloud-based patient relationship management solutions company. First Analysis provided advisory expertise to PrescribeWellness throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
About PrescribeWellness:
Headquartered in Irvine, CA, PrescribeWellness is a leading cloud-based patient relationship management company that inspires collaboration between pharmacies, payers, providers, pharmaceutical companies, and patients for better health. The company enables cooperation between disparate healthcare systems for better health across America by connecting patients to locally owned community pharmacies. Its proprietary cloud-based platform empowers pharmacists to provide more effective preventive healthcare services, which improve medication adherence, chronic disease management, transitions in care and population health. With data integration and behavioral science as the foundation, PrescribeWellness software solutions position the pharmacist at the center of community healthcare.
About Tabula Rasa HealthCare:
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications, including EireneRx and MedWise, provide solutions for a range of payers, providers and other healthcare organizations.
Exclusive financial advisor
Mirixa Corp. has been sold to Cardinal Health
First Analysis acted as the exclusive financial advisor in the sale of Mirixa, a leading healthcare technology and services company specializing in medication therapy management (MTM). First Analysis provided advisory expertise to Mirixa throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
About Mirixa Corp.:
Headquartered in Reston, VA, Mirixa was the leading provider of medication therapy management software solutions. The company’s solution and large pharmacy footprint enabled its customers to successfully engage patients, manage chronic conditions, and improve adherence and clinical outcomes while reducing healthcare costs. Cardinal Health announced that it will integrate the business into OutcomesMTM. The two will combine to offer the highest quality MTM programs for payers and enhance payable service opportunities for MTM providers. Merging MirixaPro and the OutcomesMTM Connect Platform will create efficiencies for pharmacists delivering MTM services to better support them in optimizing medication regimens and reducing medication-related problems for eligible members.
Investment banking and corporate finance services are provided through First Analysis Securities Corporation (“FASC” or “First Analysis Securities”), a subsidiary of First Analysis Corp.